Official Title
Expanded Access to Provide Selitrectinib (BAY2731954) for the Treatment of Cancers With a NTRK Gene Fusion.
Brief Summary

Selitrectinib expanded access is for minor and adult patients with cancer having a changein a particular gene (NTRK1, NTRK2, or NTRK3 gene fusion). The patients are ineligiblefor an ongoing selitrectinib clinical trial or have other considerations that preventaccess to selitrectinib through an existing clinical trial. Expanded access is intendedto treat individual patients with different types of cancers with a NTRK gene fusion,including blood cancers, who have previously received tropomyosin receptor kinase (TRK)inhibitor therapy.

No longer available
Individual Patients
Solid Tumors Harboring NTRK Fusion

Drug: Selitrectinib (BAY2731954)

Selitrectinib is administered as capsules or liquid formulation.
Other Name: Loxo-195

Eligibility Criteria

Inclusion Criteria:

- Diagnosis of cancer with a NTRK1, NTRK2, and NTRK3 gene fusion

- Previous treatment with a kinase inhibitor with known activity on TRK inhibition

- Unable to participate in an ongoing selitrectinib clinical trial

- Medically suitable for treatment with selitrectinib

Exclusion Criteria:

- Currently enrolled in an ongoing clinical study with a TRK inhibitor

Eligibility Gender
Eligibility Age
Minimum: 1 Month ~ Maximum: N/A
NCT Number
Metastatic cancer
Advanced cancer
Neurotrophic tyrosine receptor kinase (NTRK)
Fusion Positive
MeSH Terms